focus -WSS

focus

author：entertainment 2025-08-12 06:42:51 - browse：69277

Photo illustration of Covid 19 testing swabs on a blue background. — Timothy Stenzel led the FDA's diagnostics division during the Covid-19 pandemic, as the agency scrambled to push through and validate accurate Covid tests. Adobe

Timothy Stenzel, the federal regulator who led the Food and Drug Administration’s diagnostics division during the chaotic time of Covid-19 pandemic, has left the agency. The FDA confirmed Thursday that Stenzel, who led the FDA’s office of in vitro diagnostics, retired at the end of 2023.

During the early days of the pandemic, Stenzel was in the middle of a turf battle between the Centers for Disease Control and Prevention and the FDA over the regulation of Covid tests. At one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development, Politico reported at the time.

It was a hectic time. Testmakers rapidly introduced new Covid-19 screening products with little data, as it was a brand new virus. The pandemic especially laid bare FDA’s inability to control lab-developed tests (LDTs). Many of the Covid-19 PCR tests fell in this category. Early on, using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. But a STAT investigation found that the Department of Health and Human Services told the FDA to stop this measure, despite knowing that many of the tests may have been inaccurate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Congress considering partial increase for doctor pay in Medicare

knowledge

WSS

Deliver public health messages at the right time

Class action alleges UnitedHealth concealed DOJ probe

PBM executives asked to testify by House panel

Class action alleges UnitedHealth concealed DOJ probe

Has Bernie Sanders reached the limit of his pharma bullying effort?

Most antidepressants don't work on kids, teens, study finds

explore

focus

focus

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Affirmative action in medical school literally saved lives

Having children helps parents live longer, especially after age 80

Drug repurposing or repositioning? The language matters

Has Bernie Sanders reached the limit of his pharma bullying effort?

In age of alternative facts, a scholarly course on calling out crap

Chemotherapy before breast cancer surgery might fuel metastasis

Supreme Court strikes down use of affirmative action

Primary care doctor shortage won't be solved by free med school tuition

entertainment

Deliver public health messages at the right time

Novel spinal cord stimulator treats paralysis without surgery

The effects of a landmark ruling on DNA ownership are becoming clearer

Why Eli Lilly’s earnings didn’t quite live up to the hype

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

As health system earnings go up, health insurance stocks go down

focus

entertainment

knowledge

hotspot